Bioventures 2018 L.P. Mpm Sells 25,131 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2018 L.P. Mpm sold 25,131 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $7.19, for a total value of $180,691.89. Following the completion of the sale, the insider directly owned 4,177,215 shares of the company’s stock, valued at $30,034,175.85. The trade was a 0.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

• On Thursday, September 3rd, Bioventures 2018 L.P. Mpm sold 32,263 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.17, for a total value of $231,325.71.
• On Tuesday, September 1st, Bioventures 2018 L.P. Mpm sold 29,088 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.06, for a total value of $205,361.28.
• On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.99, for a total transaction of $309,370.41.
• On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.01, for a total transaction of $26,168.33.
• On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.20, for a total transaction of $280,238.40.

Entrada Therapeutics Price Performance

Shares of TRDA stock opened at $7.13 on Friday. The company’s fifty day moving average price is $7.06 and its two-hundred day moving average price is $9.19. The firm has a market capitalization of $277.64 million, a P/E ratio of -1.80 and a beta of -0.25. Entrada Therapeutics, Inc. has a 12 month low of $5.02 and a 12 month high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA) last announced its earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. The business had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.32 million. On average, sell-side analysts anticipate that Entrada Therapeutics, Inc. will post -4.03 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. HC Wainwright lowered Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Roth Capital reissued a “buy” rating and set a $11.00 price objective on shares of Entrada Therapeutics in a report on Wednesday, August 12th. Wall Street Zen raised shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Guggenheim cut their target price on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Monday, June 8th. Finally, Weiss Ratings raised shares of Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $17.75.

Institutional Investors Weigh In On Entrada Therapeutics

Institutional investors have recently made changes to their positions in the company. State of Wyoming acquired a new stake in shares of Entrada Therapeutics during the 2nd quarter valued at approximately $37,000. Russell Investments Group Ltd. boosted its holdings in Entrada Therapeutics by 72.7% in the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after purchasing an additional 3,707 shares during the period. Occudo Quantitative Strategies LP bought a new stake in Entrada Therapeutics during the second quarter valued at $68,000. Jain Global LLC bought a new stake in Entrada Therapeutics during the third quarter valued at $69,000. Finally, IHT Wealth Management LLC bought a new stake in Entrada Therapeutics during the second quarter valued at $72,000. 86.39% of the stock is currently owned by institutional investors.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.